Physician profile
Sheila E Ayers
NPI 1154657468
$859.61
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $466 · 2023: $94.49 · 2024: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $248.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $305.31 | 2021-2023 | Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $83.92 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $77.89 | 2022-2023 | Imbruvica |
| Abbvie INC. | $70.71 | 2022-2024 | |
| Clovis Oncology, INC. | $48.67 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.25 | 2024 | Jardiance |
| Boston Scientific Corporation | $46.77 | 2023-2024 | Rezum Generator, Spaceoar Vue System - 10ml |
| Eisai INC. | $45.50 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $35.84 | 2022 | |
| Medtronic, INC. | $27.27 | 2022 | |
| Seagen INC. | $21.47 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.68 | 2024 | Xifaxan |
| Pfizer INC. | $15.46 | 2024 | |
| Myriad Genetic Laboratories, INC. | $14.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.